Astellas and seagen complete enrollment in ev-103 trial cohort k combining padcev® (enfortumab vedotin-ejfv) with pembrolizumab as first-line treatment for advanced urothelial cancer

Tokyo and bothell, wash., oct. 12, 2021 /prnewswire/ -- astellas pharma inc. (tse:4503, president and ceo: kenji yasukawa, ph.d.

SGEN Ratings Summary

SGEN Quant Ranking